Majority of patients with colorectal cancer do not experience social difficulties
the ONA take:
Although the majority observe no difficulties, a portion of individuals diagnosed with colorectal cancer (CRC) do experience poor social outcomes.
Researchers based at the Leeds Institute of Cancer and Pathology, University of Leeds, St. James's University Hospital, United Kingdom, sent questionnaires to all 12- to 36-month CRC survivors diagnosed in 2010 or 2011 and treated by the English National Health Service. The questionnaire assessed clinical data, sociodemographic information, and included the Social Difficulties Inventory.
The latter inventory is a 16-item scale of social distress that reviews everyday living conditions, self and others subscales, and related items.
Approximately 82% of the 21,802 respondents completed all social distress items. (Overall response rate of the 34,467 individuals contacted was 63.3%.)
Approximately 15% OF individuals reported experiencing social distress. Multivariable analysis indicated that having three or more long-term conditions was a strong precursor to social distress.
It was determined that the majority of individuals diagnosed with CRC experience no social distress, and that the risk factors (clinical and otherwise) can be used to target support for those who are more likely to experience social difficulties.
Although the majority observe no difficulties, a portion of individuals diagnosed with colorectal cancer do experience poor social outcomes.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|